AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01386567
Drug: Androxal (enclomiphene citrate)
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules oral 1x a day~1 year
Trial: NCT01386567
Drug: Testim (topical testosterone)
RxNorm normalized name: testosterone Topical Gel [Testim]
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical~1 tube~1x a day~1 year
Trial: NCT02377271
Drug: bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment by bosentan or placebo is randomized , 125 mg twice a day
Trial: NCT04322240
Drug: Alpha lipoic acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
Trial: NCT01975675
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Trial: NCT03639987
Drug: Aducanumab
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01787851
Drug: Triheptanoin oil
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00841672
Drug: Aliskiren/amlodipine 300/10 mg tablet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Trial: NCT00841672
Drug: Amlodipine 10 mg capsule
RxNorm normalized name: amlodipine 10 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
Trial: NCT00045812
Drug: SCH-58235
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01306851
Drug: Fibrin glue
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
Trial: NCT03772340
Drug: Tradipitant
RxNorm normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00274040
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274040
Drug: Ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04423757
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
Trial: NCT02372097
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 25mg, 50mg
Trial: NCT02571491
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02571491
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
Trial: NCT00075907
Drug: Efavirenz + 2 NRTIs
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00075907
Drug: Lopinavir/Ritonavir + 2 NRTIs
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00954811
Drug: 300IU rec-LH
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: luteal alternate doses
Trial: NCT00954811
Drug: progesterone 600mg
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: luteal support
Trial: NCT04434872
Drug: Fecal Microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00902772
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mg, oral dose
Trial: NCT02884050
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: antiepilepsy drug
Trial: NCT01608750
Drug: Pantoprazol
RxNorm normalized name: Pantoprazol
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/day, oral, 28 days
Trial: NCT01103180
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Trial: NCT03364725
Drug: Glecaprevir-pibrentasvir
RxNorm normalized name: glecaprevir-pibrentasvir
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
Trial: NCT01668615
Drug: all-trans-retinoid acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg three times a day oral administration for 4 months
Trial: NCT04403724
Drug: Bupivacaine-fentanyl-Morphine.
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
Trial: NCT00116779
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
Trial: NCT01268631
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
Trial: NCT01268631
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
Trial: NCT01545648
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection
Trial: NCT00289848
Drug: sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
Trial: NCT03801135
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemocomplettan will be infused after plasma exchange procedure
Trial: NCT01352572
Drug: antidepressant response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antidepressants administration for 6 weeks under therapeutic dose responders
Trial: NCT04138901
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Trial: NCT00401648
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03566199
Drug: Panobinostat Nanoparticle Formulation MTX110
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IT
Trial: NCT03566199
Drug: Convection-Enhanced Delivery (CED)
RxNorm normalized name: CED
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo CED
Trial: NCT00101270
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00101270
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01219816
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy + Epratuzumab
Trial: NCT01219816
Drug: Epratuzumab
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine + Dexamethasone + Epratuzumab
Trial: NCT03941808
Drug: Glisodin tablet
RxNorm normalized name: GliSODin
DrugBank: GliSODin (DB17013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Trial: NCT00004008
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04526028
Drug: Fulvestrant Injectable Product
RxNorm normalized name: fulvestrant Injectable Product
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Trial: NCT04526028
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
Trial: NCT00086229
Drug: Chondroitin
RxNorm normalized name: Chondroitin
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143442
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03426592
Drug: Vitamin D3, 10000 Intl Units Oral Capsule
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Trial: NCT01211834
Drug: tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
Trial: NCT02162134
Drug: Tab. Midazolam 7.5 mg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Trial: NCT02162134
Drug: Inj. Midazolam 0.7mg/kg 45 min before surgery
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj . Midazolam 0.7 mg/kg given as premedication.
Trial: NCT02162134
Drug: Inj. Propofol 2.5mg/kg
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Trial: NCT02162134
Drug: Inj. Atracurium 0.5 mg/kg
DrugBank: Atracurium besylate (DB00732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It was given to induce muscle relaxation during anesthesia.
Trial: NCT02162134
Drug: Sevoflurane 2.5 vol %
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Trial: NCT02162134
Drug: Inj. Cefuroxime 1.5 g IV
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Trial: NCT02927249
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03197480
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive 4 monthly intravitreal injections of aflibercept
Trial: NCT00395629
Drug: Deferasirox (ICL670)
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00987272
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00987272
Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.1%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00987272
Drug: Olopatadine 0.2% Vehicle
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as placebo comparator
Trial: NCT00987272
Drug: Olopatadine 0.1% Vehicle
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as placebo comparator
Trial: NCT01294176
Drug: Lipoic Acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
Trial: NCT03760276
Drug: Voriconazole Oral Product (Vfend®)
RxNorm normalized name: voriconazole Oral Product
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Trial: NCT04460248
Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years.
Trial: NCT04768530
Drug: Nitazoxanide hydrogel
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
Trial: NCT00819104
Drug: Metoprolol XL 50mg + Amlodipine 5mg
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet,oral,OD,8 weeks
Trial: NCT00819104
Drug: Metoprolol XL 25 mg + Amlodipine 2.5mg
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet,oral,OD,8 weeks
Trial: NCT00819104
Drug: Metoprolol XL 50mg
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet,oral,OD,8 weeks
Trial: NCT00819104
Drug: Metoprolol XL 25 mg
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet,oral,OD,8 weeks
Trial: NCT00819104
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet,oral,OD,8 weeks
Trial: NCT02120352
Drug: CAB Oral Tablets
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration.
Trial: NCT02120352
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
Trial: NCT02120352
Drug: RPV
RxNorm normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
Trial: NCT01610206
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
Trial: NCT01610206
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
Trial: NCT03461185
Drug: EGFR-TK Inhibitor
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib
Trial: NCT00093756
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00093756
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00093756
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00216515
Drug: galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01124045
Drug: Difluprednate ophthalmic emulsion, 0.05%
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ocular administration
Trial: NCT00002977
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01094990
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
Trial: NCT00830154
Drug: pagoclone
RxNorm normalized name: Pagoclone
DrugBank: Pagoclone (DB04903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg BID, 0.60 mg BID
Trial: NCT01654185
Drug: AI plus Dimethyldiguanide
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AI 1 tablet per day Dimethyldiguanide 0.5 bid
Trial: NCT03658785
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
Trial: NCT03658785
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days